BioMarin agreed to acquire Alesta Therapeutics in a $275 million deal to bring a rare bone disorder asset into its skeletal disease portfolio. The company framed the transaction as a way to restock its development pipeline with a program it expects could reach a larger addressable patient population. The purchase follows BioMarin’s recent activity in the rare disease space, adding another late-stage or advanced candidate (as characterized by BioCentury reporting) to its lineup aimed at skeletal muscle and bone conditions. For investors and competitors, the Alesta acquisition signals BioMarin’s continued strategy of scaling through bolt-on pipeline assets rather than relying solely on internal discovery to defend and grow franchise value.